Sanofi Gets U.S. Approval for Rare Disease Drug

By Adria Calatayud

 

Sanofi received U.S. Food and Drug Administration approval for a new drug for a rare inherited disorder called Gaucher disease, the first treatment for neurological symptoms caused by the condition.

The French drugmaker said late Wednesday that its medicine, marketed under the Infilbray brand and also known as venglustat, was authorized in adults and pediatric patients weighing at least 15 kilograms--or 33 pounds--for type 3 Gaucher disease, one of the three major forms of the disease.

The FDA said type 3 Gaucher disease affects the brain and nervous system as harmful substances build up in the brain, causing difficulties with coordination, speech and thinking that can worsen over time.

Sanofi said Infilbray is a once-daily oral medicine designed to act across the blood-brain barrier, targeting the abnormal accumulation of fatty substances called glycosphingolipids.

A late-stage clinical trial showed the drug led to significant improvements in certain neurological manifestations of the disease like cognitive deficits and difficulty with coordination and balance, the company said.

Sanofi said Infilbray carries warnings and precautions for suicidal ideation and behavior, clouding of vision in younger patients, and adverse effects on fetal development during pregnancy.

 

Write to Adria Calatayud at adria.calatayud@wsj.com

 

(END) Dow Jones Newswires

November 19, 2026 02:02 ET (07:02 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center